

AngioDynamics to Present at the 26th Annual Canaccord Adams Summer Seminar

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Aug. 2, 2006--AngioDynamics, Inc. (NASDAQ:ANGO) today announced that its chief financial officer, Joseph G. Gerardi, will make a formal presentation at the 26th Annual Canaccord Adams Summer Seminar on Wednesday, August 9, 2006 at 3:30 PM ET. The conference will be held from August 8 - 10, 2006 at the Marriott Long Wharf Hotel in Boston.

The Canaccord Adams Summer Seminar is one of the industry's longest-running conferences focusing exclusively on growth markets. The conference will feature 200 public and private companies from the technology, healthcare, and consumer industries along with midyear updates on corporate strategies and other investment issues.

Individuals may listen to a live webcast of the presentation by logging on to the Investor Relations section of AngioDynamics' web site www.AngioDynamics.com a few minutes prior to start time to download any necessary software.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, thrombolytic products, venous system products, PTA products, and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of any future clinical trials, results of pending patent litigation and the Company's ability to protect its intellectual property, overall economic conditions, general market conditions, market acceptance, inadequate reimbursement from third party payers, effects of healthcare reform and competition as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.
Joe Gerardi, 800-772-6446 x115
www.AngioDynamics.com
or
Investor Relations Contacts:

Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100

bvoss@lhai.com

SOURCE: AngioDynamics, Inc.